Evidence map›Paper›PMID 31736328›Full record

Trial reportCirculation2020

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF.

Felipe A Martinez, Matteo Serenelli, Jose C Nicolau, Mark C Petrie, Chern-En Chiang, Sergey Tereshchenko, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod and 9 more

2 registry-linked trialsAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Circulation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03036124. Cited by 91 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03036124 phase3completed

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Ran2017Enrolled4,744Registered outcomes6Posted comparisons6ConditionsChronic Heart Failure With Reduced Ejection Fraction (HFrEF)Armsdapagliflozin, Placebo
Open the trial in the graph
NCT06286878 phase2 / phase3recruitingstarted 2021, after this paper: background citation

Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes

Ran2021Enrolled80Registered outcomes4Posted comparisons0ConditionsAcute Coronary Syndrome, Diabetes, Myocardial Infarction, Ventricular DysfunctionArmsdapagliflozin, Placebo
PMID 14502100PMID 28605608PMID 21205121PMID 26026848PMID 27295427PMID 28522450PMID 11602624PMID 27679584PMID 27470878PMID 9353988PMID 8853630PMID 8598068other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Observational
  19. Article
  20. Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Felipe A MartinezUniversidad Nacional de Córdoba, Argentina (F.M.).
Matteo SerenelliBHF Cardiovascular Research Centre, University of Glasgow, UK (M. Serenelli, M.C.P., P.J., J.J.V.M.).
Jose C NicolauInstituto do Coracao (InCor), Hospital das Clínicas Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil (J.C.N.).
Mark C PetrieBHF Cardiovascular Research Centre, University of Glasgow, UK (M. Serenelli, M.C.P., P.J., J.J.V.M.).
Chern-En ChiangGeneral Clinical Research Center and Division of Cardiology, Taipei Veterans General Hospital and National Yang-Ming University, Taiwan (C.E.-C.).
Sergey TereshchenkoDepartment of Myocardial Disease and Heart Failure, National Medical Research Center of Cardiology of Russia, Moscow (S.T.).
Scott D SolomonDivision of Cardiovascular Medicine (S.D.S.), Brigham and Women's Hospital, Boston, MA.
Silvio E InzucchiSection of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.).
Lars KøberDepartment of Cardiology, Rigshospitalet Copenhagen University Hospital, Denmark (L.K.).
Mikhail N KosiborodSaint Luke's Mid America Heart Institute, University of Missouri-Kansas City (M.N.K.).
Piotr PonikowskiCenter for Heart Diseases, University Hospital, Wroclaw Medical University, Poland (P.P.).
Marc S SabatineTIMI Study Group (M.S.S.), Brigham and Women's Hospital, Boston, MA.
David L DeMetsDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison (D.L.D.).
Monika Dutkiewicz-PiaseckaLate Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland (M.D.-P.).
Olof BengtssonLate Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (O.B., M. Söjstrand, A.M.L.).
Mikaela SjöstrandLate Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (O.B., M. Söjstrand, A.M.L.).
Anna Maria LangkildeLate Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (O.B., M. Söjstrand, A.M.L.).
Pardeep S JhundBHF Cardiovascular Research Centre, University of Glasgow, UK (M. Serenelli, M.C.P., P.J., J.J.V.M.).
John J V McMurrayBHF Cardiovascular Research Centre, University of Glasgow, UK (M. Serenelli, M.C.P., P.J., J.J.V.M.).

Funding

British Heart Foundation RE/18/6/34217
6 · The paper itself

Abstract

backgroundThe DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) showed that dapagliflozin added to other guideline-recommended therapies reduced the risk of mortality and heart failure hospitalization and improved symptoms in patients with heart failure and reduced ejection fraction. We examined the effects of dapagliflozin according to age, given potential concerns about the efficacy and safety of therapies in the elderly.

methodsPatients in New York Heart Association functional class II or greater with a left ventricular ejection fraction ≤40% and a modest elevation of NT-proBNP (N-terminal pro-B-type natriuretic peptide) were eligible. Key exclusion criteria included systolic blood pressure <95 mm Hg and estimated glomerular filtration rate <30 mL·min

resultsA total of 4744 patients 22 to 94 years of age (mean age, 66.3 [SD 10.9] years) were randomized: 636 patients (13.4%) were <55 years of age, 1242 (26.2%) were 55 to 64 years of age, 1717 (36.2%) were 65 to 74 years of age, and 1149 (24.2%) were ≥75 years of age. The rate of the primary outcome (per 100 person-years, placebo arm) in each age group was 13.6 (95% CI, 10.4-17.9), 15.7 (95% CI, 13.2-18.7), 15.1 (95% CI, 13.1-17.5), and 18.0 (95% CI, 15.2-21.4) with corresponding dapagliflozin/placebo hazard ratios of 0.87 (95% CI, 0.60-1.28), 0.71 (95% CI, 0.55-0.93), 0.76 (95% CI, 0.61-0.95), and 0.68 (95% CI, 0.53-0.88;

conclusionsDapagliflozin reduced the risk of death and worsening heart failure and improved symptoms across the broad spectrum of age studied in DAPA-HF. There was no significant imbalance in tolerability or safety events between dapagliflozin and placebo, even in elderly individuals. CLINICAL

trial registrationURL: https://www.clinicaltrials.gov. Unique identifier: NCT03036124.

Indexed as

Ventricular Function, LeftAdultAgedAged, 80 and overBenzhydryl CompoundsFemaleGlucosidesHeart FailureHospitalizationHumansMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPlacebo EffectProportional Hazards ModelsBenzhydryl CompoundsdapagliflozinGlucosidesNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)agedapagliflozinheart failureSGLT2 inhibitors

Identifiers

PMID31736328

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.